Intellectual Property

Since its inception, Oncolytics Biotech has worked to create a worldwide patent portfolio that broadly protects its products and technology. The Company continues to file for new patents to protect new inventions as they are developed. With over three hundred patents worldwide, including forty-six US patents, fifteen European patents and thirteen Canadian patents covering REOLYSIN^® technology and modified herpes and adenoviruses, Oncolytics has an exceptional proprietary position in the oncolytic virus field.

 

For more information on the patents held by Oncolytics, please to go to: 

 

U.S. Patents: 

patft.uspto.gov/ 

 

Canadian Patents: 

brevets-patents.ic.gc.ca/opic-cipo/cpd/eng/introduction.html

 

European Patents: 

epo.org/searching.html